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We retrospectively reviewed the medical records of patients with metastatic clear cell renal cell
carcinoma who received molecular targeted therapy between 2005 and 2011. Cancer-specific survival was
analyzed using the Kaplan-Meier method. Predictors of cancer-specific survival were analyzed using the
Cox regression hazards model. A total of 89 patients, consisting of 50 first line patients and 39 patients
receiving prior cytokine were included in the analysis. The two-year cancer-specific survival rate of the first-
line group was 60.2% and that of the prior cytokine therapy group was 62.1%. In univariate analysis,
Karnofsky performance status (KPS) ＜80%, time from diagnosis to treatment less than one year, bone
metastasis and C-reactive protein (CRP) ＞1.3 mg/dl in were statistically significant prognostic factors (p＜
0.05). In multivariate analysis, time from diagnosis to treatment less than one year (HR 2.46, 95%CI
1.11-5.82, p＝0.025) and CRP (HR 4.92, 95%CI 2.23-11.3, p＜0.001) were independent prognostic factors.
Time from diagnosis to treatment less than one year and CRP were independent prognostic factors in
patients who received molecular targeted therapy.
(Hinyokika Kiyo 61 : 135-139, 2015)




















Cooperative Oncology Group Performance status（ECOG
PS） 2以上，腎摘出なし，肝転移，LDH 正常上限の
1. 5倍以上，CRP＞ 0. 3 mg/dl を用いて予後分類
（SMU リスク分類）を報告した8)が，本分類が分子標
的薬時代においても有効であるか検討を行った．
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Table 1. Characteristics of patients
N (％)
Number of patients 89




















Prior nephrectomy 82 (92)
Sarcomatoid histology 11 (12)
Grade 1 : 2 : 3 : unknown 9 (10) : 40 (45) : 39 (44) : 1 (1)
Metastasis at first visit 39 (44)
Prior cytokine therapy 39 (44)
IFNα : 25, IFNα＋TS1 : 1
IFNα and IL2 : 11, IL2 : 2
Targeted therapy (Su : So : Ax : Ev : Tm)
First line 37 (42) : 43 (48) : 3 (3) : 1 (1) : 5 (6)
Second line 17 (35) : 4 (9) : 0 : 27 (56) : 0
Third line 5 (24) : 4 (19) : 0 : 7 (33) : 5 (24)
Values are N (％) except where mentioned otherwise. First line
therapy : first line therapy group, Prior therapy : prior cytokine
therapy group, Targeted therapy : time after targeted therapy,
initial therapy : time after initial therapy, IFNα : interferon alpha,
IL2 : interleukin 2, Su : sunitinib, So : sorafenib, Ax : axitinib,
Ev : everolimus, Tm : temsirolimus, First line : first line molecular
targeted therapy, Second line : second line molecular targeted
therapy, Third : third line molecular targeted therapy.
Table 2. Risk factors and metastatic sites
N (％)
Number of patients 89
MSKCC risk
Favorable risk 20 (22)
Intermediate risk 55 (62)
Poor risk 14 (16)
Risk factor
Karnofsky performance status＜80％ 10 (11)
Hb＜lower limit of normal 47 (53)
Ca≥10.0 mg/dl 22 (25)
LDH≥1.5 times upper limit of normal 3 ( 3)
Treatment＜1 year 46 (52)
Metastatic site, targeted
Lung 65 (73)
Lung without other metastatic sites 29 (33)
Bone 19 (21)
Liver 8 ( 9)
Brain 9 (10)
Others 50 (56)
CRP＞1.3 mg/dl 29 (33)
Values are N (％) except where mentioned otherwise.
Targeted : at the point of starting targeted therapy, Initial : at
the point of starting initial therapy, Hb : hemoglobin Ca :
corrected calcium, LDH : lactate dehydrogenase, Treatment
＜1 year : time from diagnosis to treatment less than 1 year,
CRP＞1.3 : C-reactive protein greater than 1.3.
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Fig. 1. Cancer-specific survival rate CSS after mole-
cular targeted therapy. Kaplan-Meier cur-
ves for cancer-specific survival rates accord-







ハザードモデルでハザード比（HR : hazard radio）を
算出した．統計学的検定は，p＜0.05 を有意差ありと
判定した．C-reactive protein（CRP）の cut-off 値は，
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Fig. 2. ROC plot for cut-off point of CRP and cancer-specific survival according to CRP level. (a) Receiver
operating characteristic plot for cut-off point of CRP to predict poor prognosis. (b) Kaplan-Meier
curves for cancer-specific survival rates stratified by serum CRP level.
Table 3. Univariate and multivariate analyses
Variable
Univariate analysis Multivariate analysis
HR (95％CI) p-value HR (95％CI) p-value
MSKCC Risk
KPS＜80％ 4.21 (1.69-9.17) 0.004 2.58 (0.88-6.85) 0.081
Hb＜LLN 1.24 (0.61-2.42) 0.524
Ca≥10 mg/dl 2.06 (0.99-4.09) 0.053
LDH≥1.5 ULN IU/l 0.75 (0.04-3.50) 0.769
Treatment＜1 year 2.03 (1.01-4.32) 0.046 2.46 (1.11-5.82) 0.025
Metastatic site
Lung 0.51 (0.22-1.05) 0.068
Bone 2.55 (1.19-5.16) 0.018 1.97 (0.89-4.13) 0.092
Liver 2.10 (0.62-5.32) 0.206
Brain 2.51 (0.94-5.67) 0.065
Cytokine therapy 0.88 (0.44-1.73) 0.710
CRP＞1.3 mg/dl 7.41 (3.62-15.7) ＜0.001 4.92 (2.23-11.3) ＜0.001
CI : confidence interval, KPS＜80％ : Karnofsky performance status less than 80％, Hb＜LLN :
hemoglobin less than lower limit of normal, Ca : corrected calcium, LDH＞1.5 ULN IU/l : lactate
dehydrogenase greater than 1. 5 times upper limit of normal, Treatment＜ 1 year : time from
diagnosis to treatment less than 1 year, Metastatic site : metastatic site at the point of starting targeted
therapy, Lung : Lung metastasis without other metastatic sites, Cytokine therapy : Prior cytokine






い cut-off 値は，ROC 曲線より以下 1.3 mg/dl とした
（Fig. 2a 感度 : 81.5％，特異度 : 70.8％）．CRP＞1.3
mg/dl は29例（32.6％）に認めた．





Karnofsky performance status（KPS）＜80％（HR 4.21，
95％CI 1.69∼9.17，p＝0.004），診断から治療開始ま
で 1 年以内（HR 2. 03，95％CI 1. 01∼4. 32，p＝
0.046），CRP ＞1.3 mg/dl（HR 7.41，95％CI 3.62∼
15.7，p＜0.001）であった．単変量解析で有意差を
認めた項目について，多変量解析を施行したところ，
診断から治療開始まで 1 年以内（HR 2.46，95％CI
1. 11∼5. 82，p＝ 0. 025），CRP ＞ 1. 3 mg/dl（HR
4.92，95％CI 2.23∼11.3，p＜0.001）で有意差を認
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Fig. 3. Cancer-specific survival according to risk group. Kaplan-Meier curves for cancer-specific survival
rates according to (a) MSKCC risk classification and (b) modified SMU classification.
Table 4. MSKCC risk and modified classification










CRP＞1.3 mg/dl 29 (33)




mg/dl 群では，82.2％，CRP＞1.3 mg/dl 群では，
9.9％であった（p＜0.001）．




いることと，SMU リスク因子に腎摘出と CRP 値が
含まれていることである．それぞれの症例数を Table
4 に示す．MSKCC リスク分類では，favorable risk 20
例（22％），intermediate risk 55例（62％），poor risk 14
例（16％）であった．また，SMU リスク分類におけ
る CRP のカットオフ値を今回の検討で用いた 1.3
mg/dl とし，favorable risk 0 個，intermediate risk 1
個，poor risk 2個以上に分類（modified SMU リスク
分類）すると，favorable risk 29例（33％），intermedi-
ate risk 42例（47％），poor risk 18例（20％）であった．
それぞれの生存率を Fig. 3a，b に示す．MSKCC リス
ク分類での 2 年癌特異的生存率は，favorable risk




















予後因子とされている12)．CRP の cut-off 値について
は，報告13)によって様々である．IL-6 に対する CRP
の反応性は個人差が大きいため11)，今回の検討では
ROC 曲線より 1.3 mg/dl を cut-off 値として検討を
行った．以前の報告よりも cut-off 値がやや高いが，

















intermediate risk と poor risk を明確に層別化すること
ができなかった．一方，SMU リスク分類を用いる
と，favorable，intermediate および poor risk に層別化
することが可能であった．
ただしサイトカイン時代の対象と異なり，リスク因
子数が favorable risk 群 0∼ 1個，intermediate risk 群 2
個，poor risk 群 3 個以上であったものを，favorable
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